DESTINY-Breast03 Phase 3 Study Results
Patient Disposition
Screened (N = 713)
Randomized 2:1 (N = 557)
TPC (n = 184)
T-DXd (n = 373)
Treated (99.5%)
Ongoing study treatment (15.6%)
•
Discontinued study treatment (84.4%)
.
•
Death (1.3%)
Adverse event (16.2%)
Progressive disease (59.3%)
• Withdrawal by subject (3.2%)
•
Other (4.3%)
10
Daiichi-Sankyo
DESTINY-Breast04
•
Treated (93.5%)
•
Ongoing study treatment (1.7%)
Discontinued study treatment (98.3%)
•
Death (1.2%)
Adverse event (8.1%)
Progressive disease (75.6%)
Withdrawal by subject (6.4%)
Othera (7.0%)
T-DXd, trastuzumab deruxtecan; TPC, treatment of physician's choice.
*Other includes clinical progression, physician decision, lost to follow-up, and other unknown reasons.
ASCO 2022 #LBA3 Plenary Session
Eribulin
Chemotherapy, n (%)
94 (51.1)
Capecitabine 37 (20.1)
Nab-paclitaxel 19 (10.3)
Gemcitabine 19 (10.3)
Paclitaxel
15 (8.2)
6View entire presentation